Next generation CAR-Treg therapies: an interview with Stéphane Boissel

In this exclusive interview, Stéphane Boissel, TxCell, discusses recent data on TxCell’s proprietary CAR-Treg cell therapies.

In this interview, filmed exclusively at the Alliance for Regenerative Medicine‘s 5th Annual European Union Investor Day, Stéphane Boissel, CEO, TxCell, discusses recent data on TxCell’s proprietary CAR-Treg cell therapies.

Speaking to RegMedNet, Stéphane also discusses TxCell’s preparations for clinical trial and commercial manufacture.

Read more about the Alliance for Regenerative Medicine on RegMedNet:

• The ‘point of the spear’ for regenerative medicine commercialization: an interview with Janet Lambert
• RegMedNet at the 5th Annual European Advanced Therapies Investor Day
• ARM and ISCT collaborating to advance regenerative medicine therapies